- Home
- CRNX vs TVTX Comparison
CRNX vs TVTX Comparison
Compare CRNX & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRNX
- TVTX
- Stock Information
- Founded
- CRNX 2008
- TVTX 2008
- Country
- CRNX United States
- TVTX United States
- Employees
- CRNX N/A
- TVTX N/A
- Industry
- CRNX Biotechnology: Pharmaceutical Preparations
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- CRNX Health Care
- TVTX Health Care
- Exchange
- CRNX Nasdaq
- TVTX Nasdaq
- Market Cap
- CRNX 2.8B
- TVTX 3.1B
- IPO Year
- CRNX 2018
- TVTX N/A
- Fundamental
- Price
- CRNX $39.96
- TVTX $31.08
- Analyst Decision
- CRNX Buy
- TVTX Strong Buy
- Analyst Count
- CRNX 12
- TVTX 15
- Target Price
- CRNX $74.45
- TVTX $37.21
- AVG Volume (30 Days)
- CRNX 1.2M
- TVTX 2.1M
- Earning Date
- CRNX 11-06-2025
- TVTX 10-30-2025
- Dividend Yield
- CRNX N/A
- TVTX N/A
- EPS Growth
- CRNX N/A
- TVTX N/A
- EPS
- CRNX N/A
- TVTX N/A
- Revenue
- CRNX $1,392,000.00
- TVTX $435,826,000.00
- Revenue This Year
- CRNX $405.68
- TVTX $108.68
- Revenue Next Year
- CRNX $1,034.87
- TVTX $40.23
- P/E Ratio
- CRNX N/A
- TVTX N/A
- Revenue Growth
- CRNX 0.51
- TVTX 114.22
- 52 Week Low
- CRNX $24.10
- TVTX $12.91
- 52 Week High
- CRNX $62.53
- TVTX $36.15
- Technical
- Relative Strength Index (RSI)
- CRNX 44.22
- TVTX 59.09
- Support Level
- CRNX $41.41
- TVTX $32.99
- Resistance Level
- CRNX $43.89
- TVTX $34.42
- Average True Range (ATR)
- CRNX 1.94
- TVTX 1.50
- MACD
- CRNX -0.41
- TVTX 0.09
- Stochastic Oscillator
- CRNX 17.99
- TVTX 46.36
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.